Preserving scientific knowledge to accelerate antibiotic discovery

This article is in partnership with:

Barry Bunin PhD

CEO Collaborative Drug Discovery

Data management technology company allows scientists and research organisations to securely manage and share drug discovery data in support of AMR innovation.


Antimicrobial resistance (AMR) is driven not only by the emergence of drug-resistant pathogens, but by another less recognised obstacle to progress: fragmentation of scientific data. “When pharmaceutical companies reduced their investment in antibiotic development due to limited commercial incentives, valuable research data risked being lost,” explains Barry Bunin, CEO of Collaborative Drug Discovery (CDD).

“Nature doesn’t care about commerciality,” he continues. “With the science underpinning drug discovery shared across many diseases, collaborative data sharing is essential to preserve existing knowledge and accelerate the development of new treatments.”

Our technology, supported by funding from the Gates Foundation, has powered major collaborative research initiatives for nearly two decades

Securing collaborative drug discovery data

Founded in 2004, CDD Vault provides secure software that scientists, biotechs and pharmaceutical companies use to manage, analyse and share drug discovery data while protecting intellectual property. AMR teams use it today to track compound activity across bacterial species, phenotypes and strain.

“Our technology, supported by funding from the Gates Foundation, has powered major collaborative research initiatives for nearly two decades, including the TB Drug Accelerator, a model that could apply to other neglected areas of AMR,” says Bunin. “Data is securely partitioned, and as the name suggests, it operates like a bank vault, private by default with system administrators controlling who has access.”

Free curated data accelerates antibiotic discovery

CDD’s SPARK initiative, developed in collaboration with the Pew Charitable Trusts and informed by leading antimicrobial research experts, including the late Lynn Silver, aims to preserve and curate antibiotic discovery data contributed by companies such as Achaogen and Novartis.

Re-SPARK is free to use for viewing and downloading your data, with access to the original SPARK Vault for any researcher; curated data from these programmes supports AI-driven antibiotic drug discovery, facilitating reliable comparisons across bacterial species, strains and antimicrobial activity.

“CDD also provides public data resources and free access for researchers in Africa working on neglected tropical diseases, funded by our commercial customers,” explains Bunin. “We enable organisations to be part of the solution to some of humanity’s greatest health challenges.”

More from AMR & Infectious Diseases